XBiotech XBIT
NASDAQ XBIT
$2.31 +0.00 (+0.00%)
At close: Aug 20, 2026 · 4:00 PM EDT

XBiotech (XBIT) Debt Ratio (2024)

XBiotech (XBIT) posted quarterly Debt Ratio of 0.0 for Q4 2024, down 97.36% quarter-over-quarter from 0.05 in Q3 2024.

XBiotech (XBIT) Debt Ratio (2024) Analysis & Trends

XBiotech's Debt Ratio history runs 1 years deep, the most recent figure standing at 0.0 for Q4 2024.

  • In Q4 2024, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Dec 2024 stood at 0.0 (changed N/A YoY), while the FY2024 annual figure was 0.0, changed N/A from the prior year.
  • Debt Ratio for Q4 2024 stood at 0.0, down from 0.05 in the prior quarter.
  • The five-year high for Debt Ratio was 0.05 in Q3 2024, with the low at 0.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 0.05
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn -
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 0.05
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 0.12
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn -
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 0.26
8 Royalty Pharma 26.98 Bn 26.14 Bn - 0.47
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 0.03
10 XBiotech 68.90 Mn 68.90 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 0.00
Sep 30, 2024 0.05
Jun 30, 2024 0.05
Mar 31, 2024 0.04